Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will earn ($0.98) per share for the quarter, up from their previous forecast of ($1.33). HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.20) EPS, FY2026 earnings at ($4.57) EPS, FY2027 earnings at ($5.47) EPS, FY2028 earnings at ($4.37) EPS and FY2029 earnings at ($2.14) EPS.
Several other equities research analysts have also recently weighed in on CRBP. Wedbush reiterated an "outperform" rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Piper Sandler began coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They issued an "overweight" rating and a $35.00 price objective for the company. Jefferies Financial Group dropped their price objective on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. William Blair began coverage on Corbus Pharmaceuticals in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $59.13.
Get Our Latest Stock Report on CRBP
Corbus Pharmaceuticals Stock Performance
CRBP stock traded down $0.14 during trading on Monday, hitting $5.90. 244,587 shares of the company traded hands, compared to its average volume of 365,745. The firm has a market capitalization of $72.11 million, a PE ratio of -1.26 and a beta of 2.63. Corbus Pharmaceuticals has a 1 year low of $5.88 and a 1 year high of $61.90. The company has a 50-day moving average of $9.06 and a 200-day moving average of $17.63.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Corbus Pharmaceuticals by 27.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock worth $114,000 after acquiring an additional 1,172 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Corbus Pharmaceuticals by 7.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company's stock valued at $469,000 after buying an additional 1,600 shares in the last quarter. Wells Fargo & Company MN increased its position in Corbus Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 2,195 shares in the last quarter. FMR LLC increased its position in Corbus Pharmaceuticals by 33.0% during the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company's stock valued at $207,000 after buying an additional 2,486 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 2,616 shares in the last quarter. Institutional investors own 64.64% of the company's stock.
Corbus Pharmaceuticals Company Profile
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Further Reading
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
